Cargando…

Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database

OBJECTIVE: To test the hypothesis that exenatide twice daily reduces the relative incidence of cardiovascular disease (CVD) events among patients with type 2 diabetes compared with other glucose-lowering agent(s). RESEARCH DESIGN AND METHODS: A retrospective database analysis was performed of the Li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Best, Jennie H., Hoogwerf, Byron J., Herman, William H., Pelletier, Elise M., Smith, Daniel B., Wenten, Made, Hussein, Mohamed A.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005487/ https://www.ncbi.nlm.nih.gov/pubmed/20929995 http://dx.doi.org/10.2337/dc10-1393

Ejemplares similares

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012)

Research: Treatment: Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study
por: Wenten, M, et al.
Publicado: (2012)

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy
por: Tobin, G S, et al.
Publicado: (2012)

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily1
por: Best, J H, et al.
Publicado: (2009)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
por: Paul, Sanjoy K, et al.
Publicado: (2015)

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
por: Rosenstock, Julio, et al.
Publicado: (2013)

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Glucagon, GLP-1 and Thermogenesis
por: González-García, Ismael, et al.
Publicado: (2019)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Exenatide at mealtimes in type 1 diabetes—no MAG1C with exenatide, or with other glucagon-like peptide-1 receptor agonists
por: Doggrell, Sheila A.
Publicado: (2020)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

Acute effects of glucagon‐like peptide‐1, GLP‐1(9–36 amide), and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers
por: Bremholm, Lasse, et al.
Publicado: (2017)

The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus
por: Lastya, Agus, et al.
Publicado: (2014)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
por: Ratner, Robert, et al.
Publicado: (2011)

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE
por: Mathieu, Chantal, et al.
Publicado: (2013)

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
por: Mitchell, James L, et al.
Publicado: (2023)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study
por: Pawaskar, Manjiri, et al.
Publicado: (2013)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
por: Simó, Rafael, et al.
Publicado: (2015)

Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
por: Li, Naichang, et al.
Publicado: (2012)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
por: Andreozzi, Francesco, et al.
Publicado: (2016)

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
por: Henry, Robert R., et al.
Publicado: (2013)

Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with Hashimoto's thyroiditis
por: Jin, Yue, et al.
Publicado: (2015)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages
por: Bułdak, Łukasz, et al.
Publicado: (2015)

Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance
por: Cacciatori, Vittorio, et al.
Publicado: (2017)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1)
por: Ang, Richard, et al.
Publicado: (2018)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
por: Ørgaard, Anne, et al.
Publicado: (2017)

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
por: Modrzynska, Justyna, et al.
Publicado: (2021)

Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes
por: Smits, M. M., et al.
Publicado: (2017)

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study
por: Matthaei, Stephan, et al.
Publicado: (2012)

Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
por: Wolffenbuttel, B. H. R., et al.
Publicado: (2016)

Ultrastructural Study on Colocalization of Glucagon-Like Peptide (GLP)-1 with GLP-2 in Chicken Intestinal L-Cells
por: NISHIMURA, Kei, et al.
Publicado: (2013)

[Gly²]-GLP-2, But Not Glucagon or [D-Ala²]-GLP-1, Controls Collagen Crosslinking in Murine Osteoblast Cultures
por: Mieczkowska, Aleksandra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ic2j1mf5i934451shq8d7q0ulv